Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD
- Address
- lock Available on a paid plan
Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD - Multispecialty Clinical Research Center
Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD is a comprehensive clinical research facility conducting diverse Phase 2 and Phase 3 trials across multiple therapeutic areas. The center demonstrates particular expertise in neurological disorders, metabolic conditions, and respiratory diseases, serving as an important research site for novel therapeutic interventions in Eastern Europe.
- Neurological research including epilepsy management (focal onset seizures, prolonged seizures), multiple sclerosis (relapsing-remitting and progressive forms), and chronic inflammatory demyelinating polyneuropathy (CIDP)
- Cardiovascular and metabolic disorders focusing on heart failure, severe hypertriglyceridemia, and obesity/overweight management
- Respiratory disease studies including COPD, asthma treatment optimization, and respiratory syncytial virus infections
- Nephrology and infectious disease research encompassing chronic kidney disease with anemia, complicated urinary tract infections, and iron-deficiency in heart failure
The center's research portfolio reflects expertise in evaluating both innovative drug delivery systems such as extended-release formulations and inhaled medications, as well as novel therapeutic mechanisms including monoclonal antibodies and RNA-based therapies. Their participation in international multicenter trials demonstrates capability in managing complex study protocols and contributing to global evidence generation for advanced therapeutics across endocrinology, immunology, and women's health conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 58 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 58 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Immunic AG2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Immunic AG3trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mnogoprofilna Bolnitsa Za Aktivno Lechenie Puls AD
lock Showing 1 of 40 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4) | Xenon Pharmaceuticals Inc. | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 58 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azetukalner | 3 | Unknown | 2023-08-11 | 2024-02-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.